Search our Database of Scientific Publications and Authors

I’m looking for a

    675 results match your criteria Blood Cancer Journal [Journal]

    1 OF 14

    Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.
    Blood Cancer J 2018 Feb 15;8(2):22. Epub 2018 Feb 15.
    Department of Pathology, The University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, 52242, Iowa, USA.

    The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.
    Blood Cancer J 2018 Feb 13;8(2):20. Epub 2018 Feb 13.
    Department of Medicine, Division of Hematology, University of Padova, Padova, Italy.
    Multiple myeloma is a post-germinal center B-cell neoplasm, characterized by the proliferation of malignant bone marrow plasma cells, whose survival and proliferation is sustained by growth factors and cytokines present in the bone marrow microenvironment. Among them, IL-6 triggers the signal downstream of its receptor, leading to the activation of the JAK/STAT pathway. The atypical GTPase RhoU lays downstream of STAT3 transcription factor and could be responsible for mediating its effects on cytoskeleton dynamics. Read More

    Chronic neutrophilic leukemia: new science and new diagnostic criteria.
    Blood Cancer J 2018 Feb 13;8(2):19. Epub 2018 Feb 13.
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
    Chronic neutrophilic leukemia (CNL) is a distinct myeloproliferative neoplasm defined by persistent, predominantly mature neutrophil proliferation, marrow granulocyte hyperplasia, and frequent splenomegaly. The seminal discovery of oncogenic driver mutations in CSF3R in the majority of patients with CNL in 2013 generated a new scientific framework for this disease as it deepened our understanding of its molecular pathogenesis, provided a biomarker for diagnosis, and rationalized management using novel targeted therapies. Consequently, in 2016, the World Health Organization (WHO) revised the diagnostic criteria for CNL to reflect such changes in its genomic landscape, now including the presence of disease-defining activating CSF3R mutations as a key diagnostic component of CNL. Read More

    The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
    Blood Cancer J 2018 Feb 9;8(2):15. Epub 2018 Feb 9.
    Mayo Clinic, Rochester, MN, USA.
    The new edition of the 2016 World Health Organization (WHO) classification system for tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under the category of myeloproliferative neoplasms (MPNs), the revised document includes seven subcategories: chronic myeloid leukemia, chronic neutrophilic leukemia, polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic leukemia-not otherwise specified and MPN, unclassifiable (MPN-U); of note, mastocytosis is no longer classified under the MPN category. In the current review, we focus on the diagnostic criteria for JAK2/CALR/MPL mutation-related MPNs: PV, ET, and PMF. Read More

    SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.
    Blood Cancer J 2018 Jan 19;8(1):11. Epub 2018 Jan 19.
    Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
    T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy with a median survival of the patients of less than two years. Besides characteristic chromosomal translocations, frequent mutations affect the ATM gene, JAK/STAT pathway members, and epigenetic regulators. We here performed a targeted mutation analysis for 40 genes selected from a RNA sequencing of 10 T-PLL in a collection of 28 T-PLL, and an exome analysis of five further cases. Read More

    Analysis of criteria for treatment initiation in patients with progressive chronic lymphocytic leukemia.
    Blood Cancer J 2018 Jan 16;8(1):10. Epub 2018 Jan 16.
    Department of Hematology, Institute of Hematology and Oncology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

    Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
    Blood Cancer J 2018 Jan 15;8(1). Epub 2018 Jan 15.
    MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
    Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence. Danazol is also effective in some persons with PMF and anemia. Responses to these drugs are typically incomplete and not sustained. Read More

    Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
    Blood Cancer J 2018 Jan 12;8(1). Epub 2018 Jan 12.
    Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
    Osteolytic bone disease is the hallmark of multiple myeloma, which deteriorates the quality of life of myeloma patients, and it affects dramatically their morbidity and mortality. The basis of the pathogenesis of myeloma-related bone disease is the uncoupling of the bone-remodeling process. The interaction between myeloma cells and the bone microenvironment ultimately leads to the activation of osteoclasts and suppression of osteoblasts, resulting in bone loss. Read More

    Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
    Blood Cancer J 2018 Jan 10;8(1). Epub 2018 Jan 10.
    Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
    Intermediate-risk acute myeloid leukemia (IR-AML) is a clinically heterogeneous disease, for which optimal post-remission therapy is debated. The utility of next-generation sequencing information in decision making for IR-AML has yet to be elucidated. We retrospectively studied 100 IR-AML patients, defined by European Leukemia Net classification, who had mutational information at diagnosis, received intensive chemotherapy and achieved complete remission (CR) at Cleveland Clinic (CC). Read More

    Polycythemia vera treatment algorithm 2018.
    Blood Cancer J 2018 Jan 10;8(1). Epub 2018 Jan 10.
    Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
    Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old. Currently available drugs for PV have not been shown to prolong survival or alter the natural history of the disease and are instead indicated primarily for prevention of thrombosis. Unfortunately, study endpoints that are being utilized in currently ongoing clinical trials in PV do not necessarily target clinically or biologically relevant outcomes, such as thrombosis, survival, or morphologic remission, and are instead focused on components of disease palliation. Read More

    Essential thrombocythemia treatment algorithm 2018.
    Blood Cancer J 2018 Jan 10;8(1). Epub 2018 Jan 10.
    Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
    Current drug therapy for myeloproliferative neoplasms, including essential thrombocythemia (ET) and polycythemia vera (PV), is neither curative nor has it been shown to prolong survival. Fortunately, prognosis in ET and PV is relatively good, with median survivals in younger patients estimated at 33 and 24 years, respectively. Therefore, when it comes to treatment in ET or PV, less is more and one should avoid exposing patients to new drugs that have not been shown to be disease-modifying, and whose long-term consequences are suspect (e. Read More

    Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients.
    Blood Cancer J 2017 Dec 27;7(12):662. Epub 2017 Dec 27.
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    In a recent International Working Group on Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) study, prior arterial events and hypertension were predictors of subsequent arterial thrombosis whereas prior venous events and age ≥65 years predicted venous thrombosis in polycythemia vera (PV). In the current study, we sought to validate the above findings and identify additional predictors of arterial versus venous thrombosis. At a median follow up of 109 months, thrombosis after diagnosis occurred in 128 (22%) patients; 82 (14%) arterial and 57 (10%) venous events. Read More

    Aggressive NK-cell leukemia: clinical subtypes, molecular features, and treatment outcomes.
    Blood Cancer J 2017 Dec 21;7(12):660. Epub 2017 Dec 21.
    Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

    MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene.
    Blood Cancer J 2017 Dec 15;7(12):651. Epub 2017 Dec 15.
    Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.

    MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma.
    Blood Cancer J 2017 Dec 15;7(12):654. Epub 2017 Dec 15.
    Research Programs Unit, Genome-Scale Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
    Despite better therapeutic options and improved survival of diffuse large B-cell lymphoma (DLBCL), 30-40% of the patients experience relapse or have primary refractory disease with a dismal prognosis. To identify biological correlates for treatment resistance, we profiled microRNAs (miRNAs) of matched primary and relapsed DLBCL by next-generation sequencing. Altogether 492 miRNAs were expressed in the DLBCL samples. Read More

    Prognostic impact of gene mutations in myelodysplastic syndromes with ring sideroblasts.
    Blood Cancer J 2017 Nov 20;7(12):630. Epub 2017 Nov 20.
    Hematology Department, University Hospital La Fe, Fernando Abril Martorell Avenue, 106, Valencia, 46026, Spain.

    CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.
    Blood Cancer J 2017 Dec 8;7(12):638. Epub 2017 Dec 8.
    Centre for Regenerative Medicine, Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
    Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia-negative myeloproliferative neoplasms (MPNs) characterized by erythrocytosis and thrombocytosis, respectively. Approximately 95% of PV and 50-70% of ET patients harbor the V617F mutation in the exon 14 of JAK2 gene, while about 20-30% of ET patients carry CALRins5 or CALRdel52 mutations. These ET CALR-mutated subjects show higher platelet count and lower thrombotic risk compared to JAK2-mutated patients. Read More

    1 OF 14